08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Oncology Venture, Topotarget deal

Newco Oncology Venture debuted and acquired exclusive, worldwide rights from Topotarget to APO010 , a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6; FASL ). In 2Q13, Oncology Venture...
07:00 , Aug 27, 2012 |  BioCentury  |  Emerging Company Profile

Edimer: Gland idea

Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of its EDI200 given either before or soon after birth will permanently correct a rare developmental disorder. The...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

APO866: Phase II data

TopoTarget said it would discontinue developing APO866 for melanoma after an open-label, European Phase II trial failed to show a response in any of the patients. The trial had not yet completed enrollment of 43...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

APO866: Preliminary Phase II data

In an open-label, European Phase II trial, 1 patient had a partial response to APO866. APO866 was well tolerated. The company gained APO866 through its 2007 acquisition of Apoxis S.A. , which had exclusive worldwide...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

APO866: Preliminary Phase II data

In an open-label, U.K. Phase II trial, patients receiving APO866 had transient reductions in white blood cells. APO866 was well tolerated. The company gained APO866 through its 2007 acquisition of Apoxis S.A. , which had...
03:11 , Dec 23, 2008 |  BC Extra  |  Clinical News

TopoTarget discontinues APO866 in melanoma

TopoTarget (CSE:TOPO) said it would discontinue developing APO866 for melanoma after an open-label, European Phase II trial failed to show a response in any of the patients. The trial had not yet completed enrollment of...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Apoxis, Topotarget deal

TOPO completed its previously announced acquisition of Apoxis for 3.6 million shares valued at DKK107.9 million ($19.5 million) based on TOPO's close of DKK30 on June 27, the day the deal closed (see BioCentury, April...
00:08 , Jun 23, 2007 |  BC Extra  |  Financial News

TopoTarget raises $64.7 million

TopoTarget (CSE:TOPO) raised DKK360 million ($64.7 million) through the sale of 12 million shares at DKK30 in a public offering in Denmark and a private placement to institutional investors elsewhere except the U.S. TOPO proposed...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Apoxis, Topotarget deal

TOPO will acquire Apoxis for E14.5 million ($19.4 million) in stock. Apoxis’ shareholders will provide Apoxis with a E4 million ($5.3 million) convertible loan prior to the deal’s close and will be eligible for more...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Clinical News

APO866: Phase II started

Apoxis began a Phase II trial. Apoxis received exclusive worldwide rights to the product from Astellas last year. Apoxis S.A. , Lausanne, Switzerland   Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan   Product: APO866 (formerly FK866)...